Compare Stocks

Date Range: 

 Johnson & JohnsonRochePfizerNovartisEli Lilly and
SymbolNYSE:JNJOTCMKTS:RHHBYNYSE:PFENYSE:NVSNYSE:LLY
Price Information
Current Price$172.20$48.26$42.81$92.39$243.50
50-Day Moving Average$167.44$46.76$39.86$91.43$225.56
52-Week Low$133.65$39.72$33.36$77.04$129.21
52-Week High$173.65$48.79$43.74$98.52$248.40
MarketRank™
Overall Score2.82.22.82.02.8
Analysis Score2.42.12.12.12.5
Community Score4.44.34.84.34.8
Dividend Score4.22.53.32.52.5
Ownership Score1.70.02.50.02.5
Earnings & Valuation Score1.31.91.31.31.9
Analyst Ratings
Consensus RecommendationBuyHoldHoldHoldBuy
Consensus Price Target$190.38$46.42$43.08$108.50$231.29
% Upside from Price Target10.55% upside-3.81% downside0.64% upside17.44% upside-5.02% downside
Trade Information
Market Cap$453.47 billion$329.62 billion$239.64 billion$211.45 billion$233.52 billion
Beta0.710.330.740.550.26
Average Volume6,103,013835,86924,035,4601,602,7372,319,225
Sales & Book Value
Annual Revenue$82.58 billion$64.54 billion$41.91 billion$48.66 billion$24.54 billion
Price / Sales5.495.115.724.359.52
Cashflow$10.89 per share$3.42 per share$3.11 per share$8.45 per share$8.88 per share
Price / Cash15.8114.1013.7610.9427.42
Book Value$24.04 per share$6.19 per share$11.42 per share$23.65 per share$6.09 per share
Price / Book7.167.803.753.9139.98
Profitability
Net Income$14.71 billion$15.25 billion$9.62 billion$8.07 billion$6.19 billion
EPS$8.03$2.65$2.22$5.75$7.93
Trailing P/E Ratio25.8918.2118.3723.3936.40
Forward P/E Ratio16.7217.4912.9713.7928.92
P/E Growth2.732.241.382.241.96
Net Margins19.92%N/A23.06%17.83%23.91%
Return on Equity (ROE)37.78%N/A26.93%25.25%132.28%
Return on Assets (ROA)14.12%N/A10.83%10.74%16.36%
Dividend
Annual Payout$4.24$0.77$1.56$2.08$3.40
Dividend Yield2.46%1.60%3.64%2.25%1.40%
Three-Year Dividend Growth19.88%N/A-10.94%13.60%42.31%
Payout Ratio52.80%29.06%70.27%36.17%42.88%
Years of Consecutive Dividend Growth59 YearsN/A1 Years1 Years1 Years
Debt
Debt-to-Equity Ratio0.46%0.26%0.51%0.46%2.28%
Current Ratio1.28%1.30%1.48%0.80%1.42%
Quick Ratio1.04%1.01%1.16%0.56%1.10%
Ownership Information
Institutional Ownership Percentage66.60%0.32%64.10%9.50%81.57%
Insider Ownership Percentage0.30%N/A0.05%0.01%0.13%
Miscellaneous
Employees134,500101,46578,500103,91435,000
Shares Outstanding2.63 billion6.83 billion5.60 billion2.29 billion959.03 million
Next Earnings Date10/12/2021 (Estimated)N/A10/26/2021 (Estimated)10/26/2021 (Estimated)8/3/2021 (Confirmed)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Insulin Market Challenges Eli Lilly, Novo Nordisk, Biocon, etc.: Increased Business Risk after COVID-19Insulin Market Challenges Eli Lilly, Novo Nordisk, Biocon, etc.: Increased Business Risk after COVID-19
manometcurrent.com - July 31 at 6:09 PM
Lilly, Kumquat Biosciences collaborate to discover, develop & commercialize small molecules that stimulate tumor-specific immune responsesLilly, Kumquat Biosciences collaborate to discover, develop & commercialize small molecules that stimulate tumor-specific immune responses
pharmabiz.com - July 31 at 12:47 AM
Eli Lilly and Company [LLY] moved down -0.48: Why It’s ImportantEli Lilly and Company [LLY] moved down -0.48: Why It’s Important
dbtnews.com - July 30 at 7:46 PM
CDC Data on Delta’s Contagion Should Boost Covid Vaccines and DrugsCDC Data on Delta’s Contagion Should Boost Covid Vaccines and Drugs
barrons.com - July 30 at 2:46 PM
Eli Lilly (LLY) to Report Q2 Earnings: Whats in the Cards?Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
finance.yahoo.com - July 30 at 2:46 PM
Whats in Store for Amgen (AMGN) This Earnings Season?What's in Store for Amgen (AMGN) This Earnings Season?
finance.yahoo.com - July 30 at 2:46 PM
Lilly, Kumquat Launch Up-to-$2B Immuno-Oncology CollaborationLilly, Kumquat Launch Up-to-$2B Immuno-Oncology Collaboration
genengnews.com - July 30 at 9:45 AM
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology dealLilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
pmlive.com - July 30 at 9:45 AM
Eli Lilly’s New Compliance Chief on His PrioritiesEli Lilly’s New Compliance Chief on His Priorities
wsj.com - July 30 at 9:45 AM
FDA Late Wednesday Approved Eli Lilly And Incyte Arthritis Drug Baricitinib, In Combination With Remdesivir, To Treat COVID-19FDA Late Wednesday Approved Eli Lilly And Incyte Arthritis Drug Baricitinib, In Combination With Remdesivir, To Treat COVID-19
benzinga.com - July 29 at 6:33 PM
Regulators approve expanded emergency use of Eli Lillys COVID-19 treatmentRegulators approve expanded emergency use of Eli Lilly's COVID-19 treatment
wthr.com - July 29 at 6:33 PM
Lilly adds on to biomarker bombardment in Alzheimers with two new donanemab analysesLilly adds on to biomarker bombardment in Alzheimer's with two new donanemab analyses
fiercebiotech.com - July 29 at 6:33 PM
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive declineLilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
finance.yahoo.com - July 29 at 6:33 PM
U.S. FDA allows Eli Lilly’s COVID-19 drug to be taken without remdesivirU.S. FDA allows Eli Lilly’s COVID-19 drug to be taken without remdesivir
theglobeandmail.com - July 29 at 1:30 PM
Eli Lilly, Kumquat Biosciences Form Cancer Collaboration >LLYEli Lilly, Kumquat Biosciences Form Cancer Collaboration >LLY
marketwatch.com - July 29 at 1:30 PM
As COVID-19 case surge, Lilly reinstates mask restrictions on all workersAs COVID-19 case surge, Lilly reinstates mask restrictions on all workers
ibj.com - July 29 at 1:30 PM
FDA Broadens Authorization of Lillys COVID TreatmentFDA Broadens Authorization of Lilly's COVID Treatment
insideindianabusiness.com - July 29 at 1:30 PM
FDA broadens existing emergency use of Lilly and Incytes baricitinib in patients hospitalized with COVID-19 requiring oxygenFDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
finance.yahoo.com - July 29 at 1:30 PM
U.S. FDA allows Lillys COVID-19 drug to be taken without remdesivirU.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir
finance.yahoo.com - July 29 at 1:30 PM
U.S. FDA allows Lilly’s COVID-19 drug to be taken without remdesivirU.S. FDA allows Lilly’s COVID-19 drug to be taken without remdesivir
financialpost.com - July 29 at 11:11 AM
Gastrointestinal Cancer Devices Market is Anticipated to Gain Moderate CAGR by 2027 Covid-19 Analysis | Eli Lilly, NovartisGastrointestinal Cancer Devices Market is Anticipated to Gain Moderate CAGR by 2027 Covid-19 Analysis | Eli Lilly, Novartis
openpr.com - July 29 at 8:06 AM
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune ResponsesLilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
finance.yahoo.com - July 29 at 8:06 AM
Lilly signs deal with Kumquat BiosciencesLilly signs deal with Kumquat Biosciences
finance.yahoo.com - July 29 at 8:06 AM
Eli Lilly and (NYSE:LLY) Receives New Coverage from Analysts at TruistEli Lilly and (NYSE:LLY) Receives New Coverage from Analysts at Truist
americanbankingnews.com - July 29 at 1:32 AM
Eli Lilly and (NYSE:LLY) Coverage Initiated by Analysts at TruistEli Lilly and (NYSE:LLY) Coverage Initiated by Analysts at Truist
marketbeat.com - July 29 at 12:15 AM
Eli Lilly and (NYSE:LLY) Reaches New 1-Year High at $246.19Eli Lilly and (NYSE:LLY) Reaches New 1-Year High at $246.19
americanbankingnews.com - July 28 at 11:13 AM
Eli Lilly and (NYSE:LLY) Receives "Buy" Rating from MizuhoEli Lilly and (NYSE:LLY) Receives "Buy" Rating from Mizuho
marketbeat.com - July 7 at 12:06 PM
3 Recession-Proof Dividend Stocks to Buy Now (LLY)3 Recession-Proof Dividend Stocks to Buy Now (LLY)
marketbeat.com - February 1 at 5:14 PM
DateCompanyBrokerageAction
7/30/2021PfizerMizuho
Boost Price Target
7/29/2021Johnson & JohnsonSVB Leerink
Reiterated Rating
7/29/2021PfizerThe Goldman Sachs Group
Set Price Target
7/29/2021PfizerMorgan Stanley
Boost Price Target
7/29/2021PfizerRoyal Bank of Canada
Set Price Target
7/29/2021PfizerSVB Leerink
Boost Price Target
7/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
7/27/2021RocheSociete Generale
Reiterated Rating
7/27/2021PfizerTruist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/23/2021RocheBarclays
Set Price Target
7/22/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
7/21/2021Johnson & JohnsonSVB Leerink
Reiterated Rating
7/21/2021RocheCowen
Initiated Coverage
7/19/2021RocheUBS Group
Reiterated Rating
7/14/2021RocheJefferies Financial Group
Upgrade
7/8/2021RocheDeutsche Bank Aktiengesellschaft
Upgrade
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021PfizerRoyal Bank of Canada
Boost Price Target
6/15/2021PfizerBerenberg Bank
Reiterated Rating
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021RocheBerenberg Bank
Reiterated Rating
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/10/2021RocheMorgan Stanley
Reiterated Rating
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/7/2021Johnson & JohnsonCredit Suisse Group
Set Price Target
6/2/2021RocheSociete Generale
Downgrade
6/1/2021Johnson & JohnsonCredit Suisse Group
Set Price Target
5/28/2021Johnson & JohnsonMorgan Stanley
Initiated Coverage
5/24/2021PfizerJPMorgan Chase & Co.
Set Price Target
5/24/2021PfizerThe Goldman Sachs Group
Set Price Target
5/13/2021PfizerThe Goldman Sachs Group
Reiterated Rating
5/12/2021PfizerMizuho
Reiterated Rating
5/11/2021NovartisMorgan Stanley
Reiterated Rating
5/10/2021PfizerMorgan Stanley
Boost Price Target
5/6/2021PfizerMizuho
Downgrade
5/5/2021PfizerSVB Leerink
Boost Price Target
5/5/2021PfizerJPMorgan Chase & Co.
Boost Price Target
5/5/2021PfizerBarclays
Boost Price Target
4/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
4/28/2021NovartisOddo Bhf
Upgrade
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/19/2021NovartisUBS Group
Reiterated Rating
4/7/2021PfizerRoyal Bank of Canada
Initiated Coverage
4/6/2021PfizerThe Goldman Sachs Group
Set Price Target
3/31/2021PfizerThe Goldman Sachs Group
Set Price Target
3/26/2021PfizerSVB Leerink
Lower Price Target
3/23/2021PfizerBerenberg Bank
Reiterated Rating
3/23/2021NovartisSociete Generale
Reiterated Rating
3/22/2021NovartisSanford C. Bernstein
Initiated Coverage
3/16/2021RocheJefferies Financial Group
Downgrade
3/16/2021NovartisArgus
Reiterated Rating
3/15/2021PfizerThe Goldman Sachs Group
Set Price Target
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/10/2021NovartisArgus
Downgrade
3/9/2021PfizerThe Goldman Sachs Group
Reiterated Rating
3/5/2021RocheErste Group
Downgrade
2/25/2021RocheBerenberg Bank
Reiterated Rating
2/24/2021RocheMorgan Stanley
Reiterated Rating
2/17/2021RocheUBS Group
Downgrade
2/12/2021Eli Lilly andCowen
Boost Price Target
2/10/2021RocheJPMorgan Chase & Co.
Reiterated Rating
2/4/2021RocheOddo Bhf
Downgrade
2/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
2/3/2021PfizerJPMorgan Chase & Co.
Set Price Target
2/2/2021NovartisMorgan Stanley
Reiterated Rating
2/1/2021NovartisCowen
Downgrade
2/1/2021Eli Lilly andTruist
Boost Price Target
2/1/2021Eli Lilly andMizuho
Boost Price Target
2/1/2021Eli Lilly andBarclays
Boost Price Target
1/27/2021Johnson & JohnsonJPMorgan Chase & Co.
Boost Price Target
1/27/2021Johnson & JohnsonCredit Suisse Group
Boost Price Target
1/27/2021Johnson & JohnsonRaymond James
Boost Price Target
1/27/2021Johnson & JohnsonCowen
Boost Price Target
1/27/2021Johnson & JohnsonMorgan Stanley
Boost Price Target
1/27/2021Johnson & JohnsonSVB Leerink
Boost Price Target
1/27/2021Johnson & JohnsonWells Fargo & Company
Boost Price Target
1/26/2021Johnson & JohnsonCantor Fitzgerald
Boost Price Target
1/22/2021RocheBarclays
Reiterated Rating
1/22/2021NovartisBarclays
Reiterated Rating
1/22/2021Eli Lilly andBank of America
Boost Price Target
1/19/2021Eli Lilly andMizuho
Upgrade
1/15/2021RocheDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/15/2021NovartisDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/12/2021RocheUBS Group
Reiterated Rating
1/12/2021Eli Lilly andTruist
Boost Price Target
1/8/2021RocheMorgan Stanley
Downgrade
1/8/2021NovartisMorgan Stanley
Reiterated Rating
1/4/2021RocheJPMorgan Chase & Co.
Downgrade
12/16/2020Eli Lilly andMizuho
Boost Price Target
12/15/2020Johnson & JohnsonMorgan Stanley
Boost Price Target
12/10/2020Eli Lilly andWolfe Research
Upgrade
12/3/2020NovartisArgus
Boost Price Target
11/27/2020RocheUBS Group
Reiterated Rating
11/25/2020NovartisUBS Group
Reiterated Rating
11/20/2020Johnson & JohnsonRaymond James
Reiterated Rating
11/10/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
10/16/2020RocheUBS Group
Reiterated Rating
10/14/2020Johnson & JohnsonCredit Suisse Group
Boost Price Target
10/14/2020Johnson & JohnsonCantor Fitzgerald
Boost Price Target
10/13/2020Johnson & JohnsonCredit Suisse Group
Set Price Target
9/29/2020RocheBerenberg Bank
Initiated Coverage
9/29/2020NovartisBerenberg Bank
Initiated Coverage
9/28/2020RocheSociete Generale
Reiterated Rating
9/23/2020NovartisOddo Bhf
Downgrade
9/10/2020NovartisUBS Group
Upgrade
9/4/2020Johnson & JohnsonCredit Suisse Group
Reiterated Rating
9/1/2020NovartisMorgan Stanley
Upgrade
8/19/2020Johnson & JohnsonStifel Nicolaus
Downgrade
8/12/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
8/3/2020Johnson & JohnsonCantor Fitzgerald
Reiterated Rating
7/28/2020NovartisMorgan Stanley
Reiterated Rating
7/20/2020Johnson & JohnsonBank of America
Reiterated Rating
7/20/2020Johnson & JohnsonIndependent Research
Upgrade
7/17/2020Johnson & JohnsonRaymond James
Boost Price Target
7/17/2020Johnson & JohnsonCitigroup
Boost Price Target
6/15/2020NovartisCitigroup
Upgrade
(Data available from 8/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.